HCV SERVICE INNOVATIONS IN DRUG TREATMENT PROGRAMS

药物治疗计划中的丙肝服务创新

• 批准号: 6379060
• 负责人: SHIELA M STRAUSS
• 金额: $ 52.7万
• 依托单位: NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6379060
• 关键词: antiviral antibody; behavioral /social science research tag; clinical research; communicable disease control; communicable disease diagnosis; counseling; drug abuse therapy; health care service evaluation; health education; health services research tag; health surveys; hepatitis C; hepatitis C virus; human subject; intravenous drug abuse

DESCRIPTION: (Applicant's Abstract) Hepatitis C (HCV) is currently the most prevalent life threatening disease among injection drug users, and complications from chronic HCV infection are likely to increase dramatically in this population in the next several years. Drug treatment programs are uniquely situated to provide critical HCV services to both IDUs and non-injecting drug users. Currently, however, there is virtually no systematic information about the drug treatment field's response to the HCV epidemic. The main purposes of the research are, therefore, to: (1) measure the extent to which three types of HCV services (education and counseling, antibody testing, and medical management and monitoring) are provided by a nationwide sample (N=800) of drug treatment programs, and compare the level of HCV related services across drug treatment modalities; (2) model the level of HCV services that these drug treatment programs provide on the basis of client characteristics, organizational structure and resources, relationships with public health organizations in the programs' environment, internal support for medical services, and the provision of other medical services (especially services for HIV and hepatitis A and B); (3) conduct case studies (N=24) of drug treatment programs in order to understand the innovation process (i.e., the adoption and development of HCV services) and the current implementation process (HCV service delivery practices and procedures); and (4) understand clients' perceptions of HCV services and the service delivery process in the case study sites, and whether their perceptions are congruent with those of staff. The research will analyze quantitative survey data to assess the structure of HCV services, and qualitative case study data to assess the innovation and implementation processes. The dissemination of research findings to the drug treatment field is expected to elevate consciousness about the need to properly respond to the HCV epidemic, assist advocates for HCV services in fostering the development of services, and assist programs that want to enhance services by informing them about "best practices."

描述：（申请人摘要） 丙型肝炎（HCV）是目前最流行的威胁生命的疾病 在注射吸毒者中，慢性HCV感染的并发症 在接下来的几年里，这一人群的数量可能会急剧增加。 药物治疗计划是唯一的位置，以提供关键的丙型肝炎服务 对注射吸毒者和非注射吸毒者的影响。然而，目前， 几乎没有关于药物治疗领域反应的系统信息 HCV的流行。因此，本研究的主要目的是：（1） 衡量三种类型的HCV服务（教育和 咨询，抗体检测，医疗管理和监测）是 由全国范围内的药物治疗计划样本（N=800）提供，并比较 不同药物治疗模式中HCV相关服务的水平;（2）模型 这些药物治疗计划提供的HCV服务水平 根据客户的特点、组织结构和资源， 与项目环境中的公共卫生组织的关系， 内部医疗服务支持，以及提供其他医疗服务 服务（特别是艾滋病毒和甲型肝炎和B型肝炎的服务）;（3）进行案例 药物治疗方案的研究（N=24），以了解创新 过程（即，HCV服务的采用和发展）以及目前 实施过程（HCV服务提供实践和程序）;以及（4） 了解客户对HCV服务和服务提供的看法 过程中的案例研究网站，以及他们的看法是否一致 与工作人员的。该研究将分析定量调查数据， 评估HCV服务的结构，以及定性案例研究数据，以评估 创新和实施过程。传播研究 药物治疗领域的研究结果有望提高人们对 正确应对HCV流行的必要性，协助HCV倡导者 服务，促进服务的发展，并协助方案， 希望通过告知他们“最佳实践”来增强服务。"